Agreement Opens Pathway for Drug Discovery Projects

Karolinska Institute spin-out Pelago Bioscience AB and AstraZeneca are collaborating on research projects applying Pelago’s Cellular Thermal Shift Assay (CETSA^®) to specific drug-target interactions and other discovery projects.  

Under the two year partnership the companies will jointly develop assay formats and methods relevant across the range of AstraZeneca’s therapeutic areas and also actively share information related to benchmarking and improvement in the use of the technology.

“We are very proud of this collaborative agreement with AstraZeneca. It will allow us to further improve the CETSA method using the knowledge and experience from one of the world’s largest drug discovery companies,” said Michael Dabrowski CEO of Pelago Bioscience.

Mike Snowden, Vice President Discovery Sciences AstraZeneca said: “CETSA is an exciting technology that will allow us to examine the interaction between a drug candidate and its protein target within the cell. We are pleased to be exploring the potential of this platform in an open collaboration with the scientists at Pelago.”